Psoriasis

Philadelphia, PA

38 Psoriasis Trials near Philadelphia, PA

Power is an online platform that helps thousands of Psoriasis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

ESK-001 for Plaque Psoriasis

Philadelphia, Pennsylvania
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1680 Participants Needed

Certolizumab Pegol for Plaque Psoriasis

Philadelphia, Pennsylvania
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 17

150 Participants Needed

Decision Aid for Psoriatic Arthritis and Psoriasis

Philadelphia, Pennsylvania
The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

100 Participants Needed

JNJ-77242113 for Plaque Psoriasis

Philadelphia, Pennsylvania
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+

675 Participants Needed

JNJ-77242113 for Plaque Psoriasis

Philadelphia, Pennsylvania
This trial is testing a new medication called JNJ-77242113 to see if it can help people with plaque psoriasis in hard-to-treat areas like the scalp, genital area, and palms/soles. The medication works by calming the immune system and slowing down skin cell growth. The goal is to find a more effective treatment for these challenging cases.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+

311 Participants Needed

Guselkumab for Psoriasis

Philadelphia, Pennsylvania
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

213 Participants Needed

Secukinumab for Nail Psoriasis

Philadelphia, Pennsylvania
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

16 Participants Needed

ESK-001 for Plaque Psoriasis

Philadelphia, Pennsylvania
This trial involves patients with plaque psoriasis who have already participated in a previous study of ESK-001. They will continue to receive ESK-001 to see if it helps reduce their symptoms. The study will last for an extended period.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

165 Participants Needed

SFA002 + Supplements for Psoriasis

Philadelphia, Pennsylvania
This trial is testing a new drug called SFA004 on people with mild to moderate chronic plaque psoriasis to see if it is safe and effective. The study will last several months, with different dosages given for the first part and follow-up for the remaining period. Researchers will use blood tests and other checks to monitor the drug's effects and safety.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

90 Participants Needed

JNJ-77242113 for Plaque Psoriasis

Philadelphia, Pennsylvania
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

731 Participants Needed

Care Coordination for Cardiovascular Prevention in Psoriatic Disease

Philadelphia, Pennsylvania
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:40 - 75

520 Participants Needed

Nivolumab for Cancer

Philadelphia, Pennsylvania
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

300 Participants Needed

Deucravacitinib for Palmoplantar Pustulosis

Philadelphia, Pennsylvania
This trial tests a pill called deucravacitinib in adults with severe PPP who haven't responded to other treatments. The medication aims to reduce inflammation and calm the immune system, improving symptoms like redness and swelling. Deucravacitinib has shown efficacy in treating moderate to severe plaque psoriasis.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

18 Participants Needed

PsA Screening Questionnaire for Psoriatic Arthritis

Philadelphia, Pennsylvania
The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously developed screening questionnaires were intended for use in the setting of a doctor's office to assist providers with referral decisions. However, these screening questionnaires are infrequently used in routine practice because of limitations with time and resources. The study will aim to develop a practical screening strategy that does not require involvement from dermatologists (or other non-rheumatology providers) and can systematically reach a broad range of psoriasis patients, including patients not attending dermatology clinics. The researchers hypothesize that disseminating questionnaires directly to patients outside of a clinic setting (direct-to-patient approach) will educate patients about their PsA risk and improve early PsA diagnoses.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

18000 Participants Needed

Ixekizumab + Tirzepatide for Psoriasis

Plymouth Meeting, Pennsylvania
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

250 Participants Needed

Tirzepatide for Psoriasis and Obesity

Plymouth Meeting, Pennsylvania
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

200 Participants Needed

Deucravacitinib for Psoriasis

Berlin, New Jersey
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1452 Participants Needed

JNJ-77242113 for Plaque Psoriasis

Exton, Pennsylvania
This trial is testing a new medication called JNJ-77242113 to see if it helps people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches. The study aims to find out if this new treatment can improve symptoms for those who have not responded well to other treatments.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+

684 Participants Needed

Subcutaneous Guselkumab for Psoriasis

East Windsor, New Jersey
This trial is testing a medication called guselkumab to see if it is safe and effective for children and teenagers with chronic plaque psoriasis. The medication aims to reduce inflammation and slow down the rapid growth of skin cells. Guselkumab is the first IL-23 specific inhibitor to be approved for the treatment of plaque psoriasis and has shown excellent safety and efficacy in previous studies.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 17

120 Participants Needed

Deucravacitinib for Psoriasis

East Windsor, New Jersey
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

360 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

Subcutaneous Risankizumab for Psoriasis

East Windsor, New Jersey
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

214 Participants Needed

JNJ-77242113 for Plaque Psoriasis

East Windsor, New Jersey
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

774 Participants Needed

Bimekizumab for Psoriasis

East Windsor, New Jersey
The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleukin IL-17A or 23.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

60 Participants Needed

LY3972406 for Psoriasis

East Windsor, New Jersey
This trial is testing a new medication called LY3972406 to see if it can help adults with moderate-to-severe plaque psoriasis. The goal is to find out if it works well and is safe to use. Plaque psoriasis causes red, scaly patches on the skin, and this medication aims to reduce these symptoms.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

75 Participants Needed

TAK-279 for Psoriasis

East Windsor, New Jersey
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1300 Participants Needed

TAK-279 for Plaque Psoriasis

East Windsor, New Jersey
This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1108 Participants Needed

Guselkumab vs Golimumab for Psoriatic Arthritis

Philadelphia, Pennsylvania
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

150 Participants Needed

Guselkumab vs Golimumab for Psoriatic Arthritis

Philadelphia, Pennsylvania
This trial will compare two medications, guselkumab and golimumab, in patients with psoriatic arthritis who did not respond well to their initial treatment. The goal is to see if switching to guselkumab is more effective than trying another similar medication. Guselkumab is used for treating moderate-to-severe plaque psoriasis in adults and has shown additional benefits in patients who did not respond well to other treatments.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3

300 Participants Needed

Telemedicine for Psoriatic Arthritis

Philadelphia, Pennsylvania
This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

87 Participants Needed

Tildrakizumab for Psoriatic Arthritis

Voorhees, New Jersey
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

510 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Psoriasis clinical trials in Philadelphia, PA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Psoriasis clinical trials in Philadelphia, PA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Psoriasis trials in Philadelphia, PA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Philadelphia, PA for Psoriasis is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Philadelphia, PA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Psoriasis medical study in Philadelphia, PA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Psoriasis clinical trials in Philadelphia, PA?

Most recently, we added JNJ-77242113 for Plaque Psoriasis, Tirzepatide for Psoriasis and Obesity and Zasocitinib for Psoriatic Arthritis to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Pennsylvania

Anxiety Clinical Trials in Pennsylvania

Schizophrenia Clinical Trials in Pennsylvania

ADHD Clinical Trials in Pennsylvania

Bipolar Disorder Clinical Trials in Pennsylvania

Multiple Sclerosis Clinical Trials in Pennsylvania

Autism Clinical Trials in Pennsylvania

Treatment Resistant Depression Clinical Trials in Pennsylvania

Borderline Personality Disorder Clinical Trials in Pennsylvania

Social Anxiety Disorder Clinical Trials in Pennsylvania

Parkinson's Disease Clinical Trials in Pennsylvania

Alzheimer's Disease Clinical Trials in Pennsylvania

By Location

Clinical Trials near Philadelphia, PA

Clinical Trials near Pittsburgh, PA

Clinical Trials near Hershey, PA

Clinical Trials near Allentown, PA

Clinical Trials near Danville, PA

Clinical Trials near Bethlehem, PA

Clinical Trials near Duncansville, PA

Clinical Trials near York, PA

Clinical Trials near Wynnewood, PA

Clinical Trials near Erie, PA

Clinical Trials near Lancaster, PA

Clinical Trials near Wilkes-Barre, PA

Other People Viewed

By Subject

29 Psoriasis Trials near Atlanta, GA

33 Psoriasis Trials near Boston, MA

43 Psoriasis Trials near Dallas, TX

22 Psoriasis Trials near Seattle, WA

35 Psoriasis Trials near San Antonio, TX

20 Psoriasis Trials near Austin, TX

38 Psoriasis Trials near Manchester, NH

42 Alzheimer's Disease Trials near Philadelphia, PA

Top Clinical Trials near Philadelphia, PA

Top Depression Clinical Trials near Philadelphia, PA

Top Breast Cancer Clinical Trials near Philadelphia, PA

Top Lung Cancer Clinical Trials near Philadelphia, PA

By Trial

JNJ-77242113 for Plaque Psoriasis

Certolizumab Pegol for Plaque Psoriasis

Secukinumab for Psoriasis

Bimekizumab for Ankylosing Spondylitis

Ustekinumab for Preventing Graft-versus-Host Disease in Blood Cancer Patients

Vagus Nerve Stimulation for Physiological Response Study

TNFi Therapy Strategies for Juvenile Spondyloarthritis

Adalimumab for Enlarged Prostate

Various Treatments for Critically Ill COVID-19 Patients

Pembrolizumab + Infliximab for Melanoma

Dantrolene for Ventricular Arrhythmias

Combination Therapy for Prostate Cancer

Related Searches

Top Psoriasis Clinical Trials near Phoenix, AZ

Top Psoriasis Clinical Trials near Richmond, VA

Top Psoriasis Clinical Trials near San Antonio, TX

Top Clinical Trials near Greenville, SC

e-Health Intervention for Cancer of the Female Reproductive System

GSK4532990 for Fatty Liver Disease

Top Glioblastoma Clinical Trials near Kansas City, MO

Bridge Device + Lofexidine for Opioid Use Disorder

Probiotics for ALS

Upper Body Warming vs Under Body Warming for Cesarean Section

Combined Measles-Mumps-Rubella-Chickenpox Vaccine for Children's Immunization

E2814 + Lecanemab for Alzheimer's Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial